Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in theme_biblio_custom() (line 367 of /home/ajbls/public_html/sites/all/modules/biblio/includes/biblio_theme.inc).

Molecular Docking of Putative Compounds in Aqueous Muntingia calabura L. Leaf Extracts with Cytochrome P450 Proteins

Asian Journal of Biological and Life Sciences,2022,11,1,136-143.
Published:May 2022
Type:Research Article
Authors:
Author(s) affiliations:

John Sylvester B Nas1*, Jose Gabriel Felipe B Enriquez1, Anton Jose Y Villa-Ignacio1, Alice Alma C Bungay2, Thucydides L Salunga3

1Department of Biology, College of Arts and Sciences, University of the Philippines Manila, Manila, PHILIPPINES.

2Department of Medical Microbiology, College of Public Health, University of the Philippines Manila, Manila, PHILIPPINES.

3Department of Science, College of Natural Sciences and Mathematics, Mindanao State University-General Santos, General Santos City, PHILIPPINES.

Abstract:

Studies claim that Muntingia calabura L. (M. calabura) exhibits antibacterial, antipyretic, antidiabetic, antioxidant, and anti-inflammatory properties. Despite these numerous claims, limited studies have shown its hepatoprotective property. Thus, we investigated the hepatoprotective property of aqueous M. calabura L. leaf extracts (AMCLE) by inhibiting salient CYP450 enzymes associated with hepatotoxicity, CYP3A4 CYP2E1, CYP1A2, and CYP2D6. Aqueous leaf extracts were subjected to phytochemical screening to identify potentially active compounds. A literature search was done to determine the specific metabolites. The identified candidates were docked with CYP450 enzymes virtually. The phytochemical screening revealed that AMCLE contains phenols, tannins, saponins, alkaloids, and flavonoids. The docking experiment showed that galangin, a flavonoid, has the highest binding affinity to the CYP450 enzymes compared to all the putative metabolites tested. Also, galangin outranked most known enzyme inhibitors, except for ritonavir and α-naphthoflavone, inhibitors of CYP3A4 and CYP1A2, respectively. These data suggest that the CYP450-associated hepatoprotective property of AMCLE may be attributed to galangin. Hence, further studies are warranted to support these findings.